Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.

Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page's revision indicator was updated from v3.6.5 to v3.6.6, indicating a platform or content update without altering the study details.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedThe page's revision label updated from v3.6.4 to v3.6.5, reflecting a version update.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing v3.6.3, indicating a software version update rather than changes to the clinical study details.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a minor update to the page's version.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.2, indicating a small update to the site template or underlying code. The core study information and its presentation remain unchanged.SummaryDifference0.1%

- Check96 days agoChange DetectedThe page adds a recruitment status note and new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the heading formatting for Intervention/Treatment as well as the revision label to v3.6.0.SummaryDifference0.5%

Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.